A First-in-Human clinical trial assessing safety of ES2B-C001 with or without Montanide in patients with HER2 expressing metastatic breast cancer.
Phase 1
Recruiting
- Conditions
- HER2 positive patients under HER2 maintenance therapy (metastatic or locally advanced, unresectable)
- Registration Number
- 2024-516333-12-00
- Lead Sponsor
- Expres2ion Biotechnologies ApS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing, recruiting
- Sex
- Not specified
- Target Recruitment
- 27
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Medical University Of Vienna
🇦🇹Vienna, Austria
Medical University Of Vienna🇦🇹Vienna, AustriaBernd JilmaSite contact+434040029800bernd.jilma@meduniwien.ac.at